Fmr LLC Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

FMR LLC boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1,532.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,752 shares of the specialty pharmaceutical company's stock after buying an additional 35,439 shares during the quarter. FMR LLC owned 0.12% of Collegium Pharmaceutical worth $1,459,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Pacer Advisors Inc. raised its holdings in shares of Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company's stock valued at $109,749,000 after purchasing an additional 821,541 shares during the last quarter. Rubric Capital Management LP grew its position in Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company's stock worth $75,139,000 after purchasing an additional 499,473 shares during the period. Principal Financial Group Inc. raised its stake in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after buying an additional 64,958 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company's stock valued at $49,314,000 after buying an additional 113,300 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Collegium Pharmaceutical by 2.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company's stock worth $33,457,000 after buying an additional 19,876 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL traded up $0.63 during mid-day trading on Monday, hitting $30.72. 460,539 shares of the company traded hands, compared to its average volume of 446,483. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock's fifty day moving average price is $33.24 and its 200-day moving average price is $34.38. The firm has a market cap of $990.72 million, a price-to-earnings ratio of 13.24 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a one year low of $28.97 and a one year high of $42.29.

Wall Street Analyst Weigh In

A number of research firms recently commented on COLL. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, HC Wainwright raised their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.